Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Rankning i aktier #16898
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Aktiekurs
$2.46
Marknadsvärde
$268.65M
Förändring (1 dag)
-1.73%
Förändring (1 år)
-57.06%
Land
CN
Handel VISEN Pharmaceuticals (2561)

Kategori

Aktiekurshistorik för VISEN Pharmaceuticals (2561)
Högsta slutkurs: $2.49 den 2026-09-01

Lägsta slutkurs: $7.66 den 2025-03-01
Aktiekurshistorik för VISEN Pharmaceuticals från 2025 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) -15.85%
2025 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$171.67 -
DE
$165.05 31.32%
DE
$38.13 25.43%
JP
$21.25 19.49%
IN
$214.66 25.92%
CH